Clinical Trials
14
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials
Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- Reistone Biopharma Company Limited
- Target Recruit Count
- 330
- Registration Number
- NCT05470413
- Locations
- 🇨🇳
The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Beijing Tongren Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳China-Japan Friendship Hospital, Beijing, Beijing, China
A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis
- First Posted Date
- 2022-01-06
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- Reistone Biopharma Company Limited
- Target Recruit Count
- 368
- Registration Number
- NCT05181137
- Locations
- 🇺🇸
Digestive Health Specialists, Dothan, Alabama, United States
🇺🇸Om Research LLC, Lancaster, California, United States
🇺🇸Yale University, New Haven, Connecticut, United States
Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous Nephropathy
- Conditions
- Primary Membranous Nephropathy
- Interventions
- Drug: SHR1459 Low DoseDrug: SHR1459 High DoseDrug: Placebo
- First Posted Date
- 2021-11-29
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- Reistone Biopharma Company Limited
- Target Recruit Count
- 61
- Registration Number
- NCT05136456
- Locations
- 🇨🇳
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Zhongshan Hospital Xiamen University, Xiamen, Fujian, China
🇨🇳The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China
Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- First Posted Date
- 2021-05-06
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- Reistone Biopharma Company Limited
- Target Recruit Count
- 336
- Registration Number
- NCT04875169
- Locations
- 🇨🇦
Dermatology Research Institute Inc., Calgary, Alberta, Canada
🇨🇦Dr Chih-ho Hong Medical Inc., Surrey, British Columbia, Canada
🇨🇦Enverus Medical Research, Surrey, British Columbia, Canada
Assess the Efficacy and Safety of SHR0302 Ointment in Adult Patients With Vitiligo
- Conditions
- Vitiligo
- Interventions
- Drug: Low Dose SHR0302 Ointment BIDDrug: High Dose SHR0302 Ointment BID
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2022-07-13
- Lead Sponsor
- Reistone Biopharma Company Limited
- Target Recruit Count
- 75
- Registration Number
- NCT04774809
- Locations
- 🇨🇳
The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
🇨🇳Dermatology Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳Wuhan No.1 Hospital, Wuhan, Hubei, China
- Prev
- 1
- 2
- 3
- Next